YH25448 240mg
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer
Trial Timeline
Jul 3, 2018 → Dec 30, 2018
NCT ID
NCT03556436About YH25448 240mg
YH25448 240mg is a phase 1 stage product being developed by Yuhan for Non-Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03556436. Target conditions include Non-Small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-Small Cell Lung Cancer were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03556436 | Phase 1 | Completed |
Competing Products
20 competing products in Non-Small Cell Lung Cancer